Edith A Perez

发表

Analysis of Population Differences in Digital Conversations About Cancer Clinical Trials: Advanced Data Mining and Extraction Study

Edith A Perez, Elizabeth M Jaffee, John Whyte, 2020, JMIR cancer.

HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization.

James N Ingle, Edith A Perez, E. Perez, 2002, Mayo Clinic proceedings.

Breast cancer management: opportunities and barriers to an individualized approach.

Edith A Perez, E. Perez, 2011, The oncologist.

Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features.

Robert Gray, Sunil Badve, Edith A Perez, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Quality assessment metrics for whole genome gene expression profiling of paraffin embedded samples

Terry M Therneau, Jeanette E Eckel-Passow, Douglas W Mahoney, 2013, BMC Research Notes.

Nanoparticle albumin-bound paclitaxel (ABI-007): a newer taxane alternative in breast cancer.

Edith A Perez, E. Perez, Alvaro Moreno-Aspitia, 2005, Future oncology.

C-MYC alterations and association with patient outcome in early-stage HER2-positive breast cancer from the north central cancer treatment group N9831 adjuvant trastuzumab trial.

Peter A Kaufman, Lyndsay N Harris, James N Ingle, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer.

Xian Zhou, Edith A Perez, E. Perez, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831.

Peter A Kaufman, James N Ingle, Edith A Perez, 2002, Journal of the National Cancer Institute.

Improving patient care through molecular diagnostics.

Lajos Pusztai, Edith A Perez, M. J. van de Vijver, 2004, Seminars in oncology.

HER2 testing: current status and future directions.

John M S Bartlett, Edith A Perez, E. Perez, 2014, Cancer treatment reviews.

Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory.

Edith A Perez, E. Perez, S. Martino, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance).

Larry Norton, Donald A Berry, Edith A Perez, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial.

Krishna R. Kalari, Jeanette E Eckel-Passow, Krishna R Kalari, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment options for patients with triple-negative breast cancer

Edith A Perez, E. Perez, Rafael Santana-Davila, 2010, Journal of hematology & oncology.

Impact of American Society of Clinical Oncology/College of American Pathologists guideline recommendations on HER2 interpretation in breast cancer.

James N Ingle, Matthew P Goetz, Edith A Perez, 2010, Human pathology.

Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes.

Fergus J Couch, Zeruesenay Desta, David A Flockhart, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

Anthony Rhodes, Lisa M McShane, Soonmyung Paik, 2006, Archives of pathology & laboratory medicine.

Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial.

Robert B Livingston, Lois Shepherd, James N Ingle, 2010, The Lancet. Oncology.

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.

Greg Yothers, Peter A Kaufman, Norman Wolmark, 2005, The New England journal of medicine.

Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.

Robert B Livingston, Dongsheng Tu, Jeffrey S Abrams, 2005, Journal of the National Cancer Institute.

Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.

John M S Bartlett, Patrick Fitzgibbons, Mitch Dowsett, 2014, Archives of pathology & laboratory medicine.

Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197.

Edith A Perez, E. Perez, S. Martino, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Advances in adjuvant therapy for breast cancer.

Edith A Perez, E. Perez, D. Slamon, 2006, Clinical advances in hematology & oncology : H&O.

Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741.

Barbara L. Smith, Robert Livingston, Richard L Schilsky, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.

John M S Bartlett, Patrick Fitzgibbons, Mitch Dowsett, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prospective Validation of a 21-Gene Expression Assay in Breast Cancer.

Virginia G Kaklamani, Soonmyung Paik, Ingrid A Mayer, 2015, The New England journal of medicine.

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

Anthony Rhodes, Lisa M McShane, Soonmyung Paik, 2007, Archives of pathology & laboratory medicine.

Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27--a randomized controlled phase III trial.

Karen A Gelmon, James N Ingle, Vered Stearns, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial.

Peter A Kaufman, James N Ingle, Edith A Perez, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.

Jong-Hyeon Jeong, Peter A Kaufman, Norman Wolmark, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831.

Jong-Hyeon Jeong, Norman Wolmark, Priya Rastogi, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

MicroRNA signatures: clinical biomarkers for the diagnosis and treatment of breast cancer.

Edith A Perez, B. Necela, E. Perez, 2011, Trends in molecular medicine.